Kanauchi M, Sawai F, Saito T, Yumura F, Kanauchi K, Hamaguchi T, Hara Y, Yoshimura K, Nishiura K, Dohi K
Gan No Rinsho. 1984 Mar;30(3):265-71.
We evaluated whether assay of tissue polypeptide antigen (TPA) in sera is valuable for the determination of cancer stages compared to other tumor markers such as CEA, AFP, beta2-microglobulin, ferritin, and elastase-1. The study population consisted of cancer patients (33 gastric cancers, 7 colo-rectal cancers and 15 hepatomas), 169 patients with benign gastro-enteric diseases and 72 healthy volunteers. The percentage of positive cases for TPA (higher than 200 u/l) was 61% in gastric cancer, 71% in colo-rectal cancer and 87% in hepatoma. In certain non-cancerous conditions, such as gastric ulcer (active stage), acute hepatitis and chronic hepatitis, the TPA levels were increased over the level of healthy volunteers. There was no significant correlation between TPA and the other tumor markers. Our study suggests that TPA may be useful in the identification and evaluation of cancer patients.
我们评估了与癌胚抗原(CEA)、甲胎蛋白(AFP)、β2-微球蛋白、铁蛋白及弹性蛋白酶-1等其他肿瘤标志物相比,血清组织多肽抗原(TPA)检测对于癌症分期判定是否有价值。研究对象包括癌症患者(33例胃癌、7例结直肠癌和15例肝癌)、169例良性胃肠疾病患者及72名健康志愿者。TPA阳性(高于200 u/l)病例的百分比在胃癌中为61%,在结直肠癌中为71%,在肝癌中为87%。在某些非癌性疾病中,如胃溃疡(活动期)、急性肝炎和慢性肝炎,TPA水平高于健康志愿者。TPA与其他肿瘤标志物之间无显著相关性。我们的研究表明,TPA可能有助于癌症患者的识别和评估。